Symptomatic cardiac toxicity is predicted by dosimetric and patient factors rather than changes in 18F-FDG PET determination of myocardial activity after chemoradiotherapy for esophageal cancer

Andre Konski, Tianyu Li, Michael Christensen, Jonathan D Cheng, Jian Q Yu, Kevin Crawford, Oleh Haluszka, Jeffrey L. Tokar, Walter Scott, Neal J Meropol, Steven J Cohen, Alan Maurer, Gary M Freedman

Research output: Contribution to journalArticlepeer-review

64 Scopus citations

Abstract

PURPOSE: To determine factors associated with symptomatic cardiac toxicity in patients with esophageal cancer treated with chemoradiotherapy.

MATERIAL AND METHODS: We retrospectively evaluated 102 patients treated with chemoradiotherapy for locally advanced esophageal cancer. Our primary endpoint was symptomatic cardiac toxicity. Radiation dosimetry, patient demographic factors, and myocardial changes seen on (18)F-FDG PET were correlated with subsequent cardiac toxicity. Cardiac toxicity measured by RTOG and CTCAE v3.0 criteria was identified by chart review.

RESULTS: During the follow up period, 12 patients were identified with treatment related cardiac toxicity, 6 of which were symptomatic. The mean heart V20 (79.7% vs. 67.2%, p=0.05), V30 (75.8% vs. 61.9%, p=0.04), and V40 (69.2% vs. 53.8%, p=0.03) were significantly higher in patients with symptomatic cardiac toxicity than those without. We found the threshold for symptomatic cardiac toxicity to be a V20, V30 and V40 above 70%, 65% and 60%, respectively. There was no correlation between change myocardial SUV on PET and cardiac toxicity, however, a greater proportion of women suffered symptomatic cardiac toxicity compared to men (p=0.005).

CONCLUSIONS: A correlation did not exist between percent change in myocardial SUV and cardiac toxicity. Patients with symptomatic cardiac toxicity received significantly greater mean V20, 30 and 40 values to the heart compared to asymptomatic patients. These data need validation in a larger independent data set.

Original languageEnglish
Pages (from-to)72-7
Number of pages6
JournalRadiotherapy and Oncology
Volume104
Issue number1
DOIs
StatePublished - Jun 2012

Keywords

  • Adult
  • Aged
  • Aged, 80 and over
  • Chemoradiotherapy
  • Esophageal Neoplasms/therapy
  • Female
  • Fluorodeoxyglucose F18
  • Heart/diagnostic imaging
  • Humans
  • Male
  • Middle Aged
  • Positron-Emission Tomography
  • Radiopharmaceuticals
  • Radiotherapy Dosage
  • Retrospective Studies

Fingerprint

Dive into the research topics of 'Symptomatic cardiac toxicity is predicted by dosimetric and patient factors rather than changes in 18F-FDG PET determination of myocardial activity after chemoradiotherapy for esophageal cancer'. Together they form a unique fingerprint.

Cite this